KZA 0.00% 38.5¢ kazia therapeutics limited

marshall edwards inc has four studies at the us aa

  1. 22,691 Posts.
    31 MARCH 2004

    Investigational anti-cancer drug phenoxodiol produces response and restores chemo-sensitivity in four
    Novogen Limited’s subsidiary, Marshall Edwards, Inc. (LSE AIM: MSH and Nasdaq: MSHL) has just made the following
    announcement to the London Stock Exchange’s Alternative Investment Market.

    Late-breaking Phase 2 prostate cancer study data included at AACR (Orlando, Florida March 31, 2004)

    Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR) in Orlando, Florida, confirms that phenoxodiol is on track in its development as a first-line therapy for early-stage cancers and as a chemo-sensitizing agent for late-stage cancers.

    Phenoxodiol, a XIAP-inhibitor, is an anticancer
    drug being developed by Marshall Edwards, Inc., (Nasdaq: MSHL). The data presented concerned clinical studies conducted at U.S. and Australian hospitals, and pre-clinical studies conducted at U.S. research institutions.

    Interim results of phase 1b/2a data shows dose-related response
    Late breaking data from a Phase 1b/2a clinical trial in late-stage prostate cancer patients supports the strategy of targeting this cancer type. Twenty-four patients with malignant prostate cancer and rising prostate specific antigen (PSA) levels
    (mean 60 ng/mL at start of study) were treated with phenoxodiol (oral dosage formulation) 3 times daily, for 3 weeks each month up to a maximum of 6 months.

    Patients received 1 of 4 different dosages – 20, 80, 200 or 400 mg. There were 6 patients per dose stratum.
    This first trial of oral phenoxodiol was designed to confirm that the dosage form was biologically active.

    Activity was
    determined on the basis of PSA levels in the blood. PSA, a protein normally secreted by the prostate, is a marker commonly used to detect the presence of prostate cancer.

    Although not an absolute predictor of prostate cancer, it is generally accepted that as prostate cancer develops, a greater amount of PSA is released into the blood stream.

    Objective tumor response was not an aim of this study.
    Interim results indicate that oral phenoxodiol is biologically active as evidenced by a dose-dependent effect on serum PSA level.

    When the 12 patients treated with the 2 highest dosages (200 and 400 mg) were tested after 3 months of therapy, 2 showed stabilization of their PSA levels, while 6 (50%) showed a decrease in PSA levels.

    Two of these 6 responders showed a decline in PSA levels of greater than 75%. No toxicity was reported.

    The clinical study was conducted in Australia by Dr. Robert Davies of Sir Charles Gairdner Hospital in Perth, Professor Alastair Tulloch of St John of God Hospital, Perth, and Dr. Mark Frydenberg of Monash Medical Centre, Melbourne.

    Dr. Davies said, “Late-stage prostate cancer is notoriously unresponsive to anti-cancer therapies, so to see this degree of response to phenoxodiol confirms our confidence in this investigational drug.”

    He also said, “While the results of this study suggest that phenoxodiol may be having a significant anti-cancer effect in its own right in prostate cancer, we believe that it has the potential to provide even greater benefit when used in combination with other drugs.”

    Dr. Graham Kelly, Executive Chairman of Marshall Edwards, Inc., said, “These data justify moving to the next step, which is a larger trial to test for objective tumor response to both phenoxodiol alone and in combination with chemotherapy, in men
    with late stage prostate cancer.”

    Yale University study shows monotherapy response in advanced ovarian cancer.

    The second set of clinical trial data discussed at the conference concerned the intravenous dosage formulation of phenoxodiol.

    This was a Phase 2 study of monotherapy phenoxodiol in 40 patients with late-stage, unresponsive, recurrent
    ovarian cancer.
    On average, these patients had undergone 5 different chemotherapy regimens, and all patients failed to respond to salvage therapy.

    The patients were treated with phenoxodiol in an attempt to determine whether phenoxodiol had any anti-tumor effect in such late-stage tumors, and if so, to identify the appropriate dosage to be used in a follow-up study where it would be used in combination with standard chemotoxic drugs.

    Intravenous phenoxodiol was administered on 2 consecutive days per week; patients were randomized to 4 dose levels – 1, 3, 10 and 20 mg/kg. Treatment continued until patients showed disease progression.

    Response to therapy was assessed on the basis of a fall in blood levels of the ovarian tumor marker (CA125), shrinkage of the tumor mass, or improved clinical

    Ten (25%) of the 40 patients had responded when assessed after 6 weeks of treatment, although tumor mass was not assessed at this time.

    In 6 of these patients, CA125 levels had fallen by an average 54%; in the other 4 patients, rapidly
    rising CA125 levels before the trial commenced had stopped rising (stabilization) at 6 weeks.

    At 3 months, 4 of these 10 patients showed stabilized CA125 levels. Almost all of these responders were in the 2 lowest dosage groups, confirming laboratory studies that showed a greater anti-tumor effect for ovarian cancer at lower dosages for phenoxodiol.

    Phenoxodiol restores chemo-sensitivity in patients with advanced ovarian cancer Relevant data, however, in terms of the company strategy of developing phenoxodiol as a chemo-sensitizing agent for latestage
    cancers, came from the follow-up management of these patients.

    Following completion of the phenoxodiol therapy
    because of disease progression, a number of the patients were re-challenged with standard chemotoxic drugs in order to test what effect phenoxodiol therapy had on their sensitivity to standard anti-cancer drugs.

    Because all patients had recurrent disease despite being heavily treated with chemotherapy, a clinical response to further chemotherapy was considered unlikely.

    In 10 patients who received paclitaxel, 8 of the 10 responded with an immediate and marked decline (average 64%) in their CA125 levels; the other 2 women failed to respond and showed progressive disease.

    Five of the 10 women treated with paclitaxel were previously considered either resistant or refractory to paclitaxel (that is, their disease previously either had
    recurred within 6 months of paclitaxel therapy, or continued to worsen despite paclitaxel therapy).

    However, after treatment with phenoxodiol and subsequent treatment with paclitaxel, 4 of these 5 patients showed a marked response in their CA125 levels, and 3 remain alive after an average of 292 days.

    These patients have yet to be assessed radiographically to determine the degree of objective tumor response.

    Dr. Thomas Rutherford of the Yale University School of Medicine, and Principal Investigator in the study, said, “we are excited that phenoxodiol has been able to provide an effect in women whose disease has been so heavily pre-treated and for whom we have run out of options”.

    “But we have always believed that the best way to use the drug was as a chemo-sensitizer, restoring the cancer cell’s susceptibility to standard drugs once they have become resistant to those drugs,” Rutherford added. “That is why this preliminary finding with phenoxodiol and paclitaxel is so exciting.

    We have seen women positively respond to paclitaxel
    after being pre-treated with phenoxodiol despite their earlier resistance to paclitaxel.”

    Dr. Kelly said, “This trial represents the first stage of a two-part program to develop phenoxodiol as a chemo-sensitizer in ovarian cancer patients. The trial has been successful in helping us identify an appropriate, well-tolerated dose of 3 milligrams per kilogram.”

    Laboratory data from Yale shows phenoxodiol restores chemo-sensitivity to a broad range of chemotherapy
    In a pre-clinical study conducted by Yale University and reported on by Gil Mor M.D., Associate Professor, Department of Obstetrics and Gynecology, phenoxodiol was shown to restore sensitivity in ovarian cancer cells not only to taxane drugs such as Taxotere® (docetaxol), but also to platinum agents such as carboplatin.

    Additionally, phenoxodiol in combination
    with gemcitabine had a comparable response. Significantly, ovarian cancer cells resistant to each of these cytotoxic drugs showed an over 100-fold increase in their sensitivity to chemotherapy following pre-treatment with phenoxodiol.

    Dr. Mor said, “What makes the results of this laboratory study so significant is the confirmation that phenoxodiol has the capacity to reverse chemo-resistance in ovarian cancer patients”.

    “Chemo-resistance is one of the greatest problems we face in cancer therapy. Almost every patient with advanced ovarian cancer ultimately becomes resistant to all anti-cancer drugs. We believe that phenoxodiol is a tool to overcome this problem so we can offer these patients renewed hope.”

    NIH laboratory study shows phenoxodiol kills head and neck cancer cells.

    In an additional pre-clinical study conducted by the NIH and reported on at the conference, the means by which
    phenoxodiol was able to stop head and neck cancer cells (squamous cell carcinomas) from growing, was described.

    Of particular relevance, however, was the fact that phenoxodiol was able to stop the growth in the laboratory of head and neck cancer cells and salivary gland cancer cells that were highly resistant to standard anti-cancer drugs.

    Mechanisms of action: phenoxodiol induces apoptosis by disrupting intra-cellular proteins Phenoxodiol has been developed as a highly selective inducer of apoptosis in tumor cells that works by removing the intracellular proteins (XIAP, c-FLIP) that play a major role in ensuring the survival of cancer cells.

    Removal of these proteins has the dual effect of rendering the cancer cell susceptible to the body’s normal defense mechanisms as well as making it more
    sensitive to the cytotoxic effects of standard anti-cancer drugs.

    The highly selective nature of phenoxodiol means that the drug has no discernible adverse effects on non-tumor cells, and its ability to enhance the killing effect of other chemotoxics is restricted to tumor cells.

    Marshall Edwards, Inc., is developing phenoxodiol on two broad therapeutic strategies. First, as a first-line therapy for early-stage cancer (including prostate and cervical cancers) where early detection is possible, and where the cancer is particularly prone to the apoptotic effect of phenoxodiol alone.

    Second, as a first-line therapy for late-stage cancers
    (including prostate carcinoma and renal carcinoma) to improve the responsiveness to standard chemotoxics in cancers that are intrinsically poorly sensitive to such drugs, or as a second-line therapy to restore responsiveness to standard chemotoxics in cancers (including ovarian carcinoma) that have acquired resistance to such drugs.

    Phenoxodiol has IND status within the U.S. and has not yet been evaluated by the FDA for marketing approval.

    Phenoxodiol, an investigational anti-cancer drug developed by pharmaceutical company, Marshall Edwards, Inc. Marshall Edwards, Inc., manages its international research and development programs using the expertise and clinical research capabilities of universities and hospitals in the U.S., Australia and Europe.

    Marshall Edwards, Inc., has licensed rights to bring phenoxodiol to market globally from its parent company, Novogen Limited. (Nasdaq: NVGN). Novogen is developing a range of therapeutics across the fields of oncology, cardiovascular disease and inflammatory diseases based on its phenolic drug technology platform.

    + + NRT Information posts:

    1. Replace your existing URL by the word: sharetrader

    2. The search engine gives a number of versions- select "Sharetrader--NRT--Novogen"

    3. Page 8 (top right corner) shows up. Amend this to page 9.

    4. The first 2 posts are the Information Posts.


    Gerry Stolwyk

    Investment carries risk and the supply of this information is not an invitation to buy any discussed stocks.

    Please do your own research and you decide if and when to buy, hold or sell any stock.
    I use TA to determine entry and exit points.

    Please note that any quoted prices may now be incorrect.

watchlist Created with Sketch. Add KZA (ASX) to my watchlist
(20min delay)
Mkt cap $18.63M
Open High Low Value Volume
38.5¢ 38.5¢ 38.0¢ $6.404K 16.66K

Buyers (Bids)

No. Vol. Price($)
1 5354 38.5¢

Sellers (Offers)

Price($) Vol. No.
39.5¢ 2532 1
Last update - 14.12pm 22/10/2018 (20 minute delay) ?
0.00 ( 10.5 %)
Open High   Low Volume
38.5¢ 38.5¢   38.5¢ 688
Last updated 14.12pm 22/10/2018 (live) ?
KZA (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.